Raymond James & Associates Axsome Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 8,701 shares of AXSM stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,701
Previous 8,643 0.67%
Holding current value
$1.11 Million
Previous $695,000 12.37%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$78.93 - $95.84 $4,577 - $5,558
58 Added 0.67%
8,701 $781,000
Q2 2024

Jul 19, 2024
SELL
$65.72 - $80.5 $12,223 - $14,973
-186 Reduced 2.11%
8,643 $695,000
Q1 2024

Apr 22, 2024
BUY
$69.39 - $97.64 $236,758 - $333,147
3,412 Added 62.99%
8,829 $704,000
Q4 2023

Jan 16, 2024
SELL
$57.42 - $83.61 $2,928 - $4,264
-51 Reduced 0.93%
5,417 $431,000
Q3 2023

Oct 24, 2023
SELL
$69.25 - $82.21 $180,257 - $213,992
-2,603 Reduced 32.25%
5,468 $382,000
Q2 2023

Jul 25, 2023
BUY
$58.41 - $90.35 $181,071 - $280,085
3,100 Added 62.36%
8,071 $579,000
Q1 2023

Apr 14, 2023
SELL
$58.39 - $75.0 $112,283 - $144,225
-1,923 Reduced 27.89%
4,971 $306,000
Q4 2022

Feb 08, 2023
BUY
$39.94 - $79.72 $38,861 - $77,567
973 Added 16.43%
6,894 $531,000
Q3 2022

Oct 25, 2022
BUY
$36.06 - $69.85 $540 - $1,047
15 Added 0.25%
5,921 $264,000
Q2 2022

Aug 12, 2022
BUY
$21.74 - $46.75 $6,021 - $12,949
277 Added 4.92%
5,906 $226,000
Q1 2022

May 11, 2022
BUY
$23.7 - $41.39 $4,621 - $8,071
195 Added 3.59%
5,629 $233,000
Q4 2021

Feb 08, 2022
BUY
$30.7 - $43.36 $166,823 - $235,618
5,434 New
5,434 $205,000
Q3 2021

Nov 02, 2021
SELL
$19.91 - $68.26 $142,037 - $486,966
-7,134 Closed
0 $0
Q2 2021

Aug 11, 2021
BUY
$50.63 - $73.5 $166,977 - $242,403
3,298 Added 85.97%
7,134 $481,000
Q4 2020

Feb 12, 2021
SELL
$66.31 - $86.52 $11,073 - $14,448
-167 Reduced 4.17%
3,836 $313,000
Q2 2020

Jul 28, 2020
SELL
$49.87 - $98.69 $13,165 - $26,054
-264 Reduced 6.19%
4,003 $329,000
Q1 2020

Apr 21, 2020
SELL
$41.2 - $101.31 $140,409 - $345,264
-3,408 Reduced 44.4%
4,267 $251,000
Q4 2019

Feb 12, 2020
SELL
$16.71 - $106.24 $262,280 - $1.67 Million
-15,696 Reduced 67.16%
7,675 $793,000
Q3 2019

Nov 07, 2019
SELL
$20.24 - $29.16 $40,480 - $58,320
-2,000 Reduced 7.88%
23,371 $473,000
Q2 2019

Aug 06, 2019
BUY
$13.46 - $25.75 $341,493 - $653,303
25,371 New
25,371 $653,000

Others Institutions Holding AXSM

# of Institutions
351
Shares Held
36.3M
Call Options Held
1.77M
Put Options Held
1.16M
View Full List

About Axsome Therapeutics, Inc.

AXSM Quotes by TradingView
  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $5.47B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email